Diabetic macular edema (DME) associated with diabetic retinopathy (DR) is a rapidly evolving market as a result of multiple intravitreal pharmacotherapy product approvals across different drug…
Diabetic macular edema (DME) associated with diabetic retinopathy (DR) is a rapidly evolving market as a result of multiple intravitreal pharmacotherapy product approvals across different drug…
TreatmentTrends: Diabetic Retinopathy/Diabetic Macular Edema (EU) is the inaugural report in an annual syndicated report series that offers a snapshot of the diabetic retinopathy (DR) and diabetic…
Type 2 diabetes (T2D) is a chronic, progressive metabolic disease in which the body becomes resistant to insulin, most often as a result of obesity and sedentary lifestyle. The primary goal of…
Type 2 diabetes (T2D) is a chronic, progressive metabolic disease in which the body becomes resistant to insulin, most often as a result of obesity and a sedentary lifestyle. The primary goal of…
TreatmentTrends: Diabetic Retinopathy/Diabetic Macular Edema 2015 (US) is the fourth annual syndicated report series that offers a snapshot of DR and DME market dynamics and the competitive…
Diabetes is a chronic, progressive metabolic disease in which the body lacks or is resistant to endogenous insulin, leading to a state of persistent high blood sugar (referred to as hyperglycemia…
Diabetic retinopathy (DR) is characterized by progressive damage to the blood vessels in the retina of a diabetic patient, from which fluid may leak causing the macula to swell. Swelling of the…
This report provides detailed analysis of the current and projected mar-kets for diabetic retinopathy (DR) and diabetic macular edema (DME). The DR population represents more than 5.8 million…